VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2022 | An insight into the CADENZA study: pivekimab sunirine in patients with R/R BPDCN

Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the CADENZA study (NCT03386513) which is evaluating the use of pivekimab sunirine in patients with relapsed/refractory (R/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN), and further highlights the promise of CD123-targeted therapy in this field.This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter